OSCAR HEALTH, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.64 USD | -2.43% |
|
+20.09% | +136.50% |
| May. 09 | Goldman Sachs Adjusts Price Target on Oscar Health to $21 From $16, Maintains Neutral Rating | MT |
| May. 07 | Sector Update: Health Care Stocks Advance in Late Afternoon Trading | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1,645 | 528.3 | 2,066 | 5,127 | - | - |
| Enterprise Value (EV) 1 | 540.7 | -732.3 | 494.5 | 3,081 | 2,351 | 1,579 |
| P/E ratio | -2.45 x | -0.86 x | -7.5 x | - | 37.5 x | 17.3 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 0.61 x | 0.1 x | 0.35 x | 0.59 x | 0.5 x | 0.44 x |
| EV / Revenue | 0.2 x | -0.14 x | 0.08 x | 0.36 x | 0.23 x | 0.13 x |
| EV / EBITDA | -1.26 x | 1.58 x | -10.9 x | 14.6 x | 6.44 x | 2.83 x |
| EV / FCF | - | - | -1.66 x | 9.72 x | 7.21 x | - |
| FCF Yield | - | - | -60.2% | 10.3% | 13.9% | - |
| Price to Book | 0.99 x | 0.6 x | - | - | - | - |
| Nbr of stocks (in thousands) | 209,516 | 214,755 | 225,797 | 236,909 | - | - |
| Reference price 2 | 7.850 | 2.460 | 9.150 | 21.64 | 21.64 | 21.64 |
| Announcement Date | 2/10/22 | 2/9/23 | 2/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,648 | 2,713 | 5,335 | 5,865 | 8,676 | 10,220 | 11,703 |
| EBITDA 1 | - | -429.8 | -462.3 | -45.24 | 211 | 365.3 | 557.3 |
| EBIT | - | -544.5 | -589.9 | -235.6 | - | 258.4 | 338.7 |
| Operating Margin | - | -20.07% | -11.06% | -4.02% | - | 2.53% | 2.89% |
| Earnings before Tax (EBT) 1 | - | -570.6 | -610.1 | -267.3 | -24.9 | 190 | 385 |
| Net income 1 | - | -572.6 | -606.3 | -270.7 | -25.8 | 173.7 | 353 |
| Net margin | - | -21.11% | -11.37% | -4.62% | -0.3% | 1.7% | 3.02% |
| EPS | -4.720 | -3.200 | -2.850 | -1.220 | - | 0.5767 | 1.250 |
| Free Cash Flow 1 | - | - | - | -297.7 | 317.1 | 326.1 | - |
| FCF margin | - | - | - | -5.08% | 3.66% | 3.19% | - |
| FCF Conversion (EBITDA) | - | - | - | - | 150.28% | 89.27% | - |
| FCF Conversion (Net income) | - | - | - | - | - | 187.77% | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 2/5/21 | 2/10/22 | 2/9/23 | 2/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 705.5 | 1,324 | 1,368 | 1,309 | 1,333 | 1,463 | 1,529 | 1,441 | 1,432 | 2,142 | 2,234 | 2,175 | 2,124 | 2,591 | 2,540 |
| EBITDA 1 | -164 | -37.04 | -75.8 | -160 | -189.7 | 51.07 | 35.57 | -20.28 | -111.6 | 219.3 | 92.93 | - | -109.4 | 280.6 | 144.6 |
| EBIT 1 | -196.3 | -68.53 | -106.5 | -192.4 | -222.5 | -25.36 | -6.529 | -58.24 | -145.5 | 185.6 | 86.36 | - | -126.3 | 174.9 | - |
| Operating Margin | -27.82% | -5.17% | -7.78% | -14.69% | -16.69% | -1.73% | -0.43% | -4.04% | -10.16% | 8.66% | 3.86% | - | -5.95% | 6.75% | - |
| Earnings before Tax (EBT) 1 | -197.9 | - | -111.8 | -195.2 | - | - | - | -64.79 | -150.6 | 178.5 | 50.15 | -47.3 | -193.1 | 231.8 | 106.3 |
| Net income 1 | -198.9 | -75.15 | -112.2 | -192.9 | -226 | -39.77 | -15.53 | -65.4 | -150 | 177.4 | 50.15 | -47.3 | -193.1 | 231.8 | 106.3 |
| Net margin | -28.2% | -5.67% | -8.2% | -14.73% | -16.96% | -2.72% | -1.02% | -4.54% | -10.48% | 8.28% | 2.24% | -2.18% | -9.09% | 8.95% | 4.19% |
| EPS 2 | -0.9500 | -0.3600 | -0.5300 | -0.9100 | -1.050 | -0.1800 | -0.0700 | -0.2900 | -0.6600 | 0.6200 | 0.1667 | -0.1633 | -0.5733 | 0.7700 | 0.3500 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/10/22 | 5/10/22 | 8/11/22 | 11/8/22 | 2/9/23 | 5/9/23 | 8/8/23 | 11/7/23 | 2/7/24 | 5/7/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 1,104 | 1,261 | 1,572 | 2,045 | 2,776 | 3,547 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | -298 | 317 | 326 | - |
| ROE (net income / shareholders' equity) | - | -77.5% | -53.2% | -32% | -4.53% | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | 7.920 | 4.120 | - | - | - | - |
| Cash Flow per Share 2 | - | -1.020 | 1.790 | -1.230 | 7.430 | 8.060 | - |
| Capex 1 | - | 25.9 | 29 | 25.6 | 34 | 41 | 47.5 |
| Capex / Sales | - | 0.95% | 0.54% | 0.44% | 0.39% | 0.4% | 0.41% |
| Announcement Date | 2/5/21 | 2/10/22 | 2/9/23 | 2/7/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
21.64
USD
Average target price
23
USD
Spread / Average Target
+6.28%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +136.50% | 5.13B | |
| +26.90% | 10.79B | |
| +2.53% | 6.64B | |
| +19.97% | 6.25B | |
| +0.95% | 2.39B | |
| -15.44% | 1.08B | |
| +135.42% | 949M | |
| -0.42% | 839M | |
| +6.42% | 160M | |
| -6.17% | 70.96M |
- Stock Market
- Equities
- OSCR Stock
- Financials Oscar Health, Inc.
